The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health•
Capsugel Lonza — A Better Way to Deliver Microbiome-Based Therapies

Latest in the News

All News →
Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development
 CLINICAL & MANUFACTURING

Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development

Microbiotica’s Series C, led by British Business Bank, will take its once-daily oral ulcerative colitis candidate MB310 into a randomised Phase 2 study after positive Phase 1b results.

BY Microbiome Times · OCT 16, 2026 · 5 MIN READ
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment
EDITOR'S CHOICE

Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment

SEP 28, 2026
Claude Discovers Novel Enzyme System with CRISPR-like Repeats
GMO & SYNBIO

Claude Discovers Novel Enzyme System with CRISPR-like Repeats

SEP 25, 2026
New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia
CLINICAL & MANUFACTURING

New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia

SEP 24, 2026
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
CLINICAL & MANUFACTURING

MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination

SEP 18, 2026
Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health
FINANCE

Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health

SEP 16, 2026
Evonik EUDRACAP colon - GMP quality targeted drug delivery from the upper small intestine to the ileo-colonic region

Editor's Choice

All Editor's Choice →
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment
 Editor's Choice

Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment

Prokarium’s live bacterial immunotherapy ZH9 aims to redefine the non-muscle invasive bladder cancer treatment paradigm, building upon the precedence of BCG with a product designed for real-world urology practice.

BY Nick Glanville, Livija Deban and Dara Henry · SEP 28, 2026 · 9 MIN READ
A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
Editor's Choice

A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

SEP 1, 2026
Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?
Editor's Choice

Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?

AUG 10, 2026